Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $10.68 down -11.44% from its previous closing price of $12.06. In other words, the price has decreased by -$11.44 from its previous closing price. On the day, 2.54 million shares were traded. ARWR stock price reached its highest trading level at $11.96 during the session, while it also had its lowest trading level at $10.655.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.09 and its Current Ratio is at 6.09. In the meantime, Its Debt-to-Equity ratio is 16.58 whereas as Long-Term Debt/Eq ratio is at 16.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 13 ’25 when Anzalone Christopher Richard sold 51,425 shares for $15.07 per share. The transaction valued at 774,975 led to the insider holds 4,062,377 shares of the business.
Anzalone Christopher Richard bought 51,425 shares of ARWR for $774,785 on Mar 13 ’25. On Mar 03 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 166,667 shares for $18.03 each. As a result, the insider received 3,005,006 and left with 3,907,135 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 1466545536 and an Enterprise Value of 1671424768. For the stock, the TTM Price-to-Sale (P/S) ratio is 586.62 while its Price-to-Book (P/B) ratio in mrq is 25.50. Its current Enterprise Value per Revenue stands at 668.57 whereas that against EBITDA is -2.756.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.92, which has changed by -0.5844358 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $30.41, while it has fallen to a 52-week low of $11.60. The 50-Day Moving Average of the stock is -38.36%, while the 200-Day Moving Average is calculated to be -49.43%.
Shares Statistics:
For the past three months, ARWR has traded an average of 1.94M shares per day and 1801970 over the past ten days. A total of 125.57M shares are outstanding, with a floating share count of 114.16M. Insiders hold about 16.87% of the company’s shares, while institutions hold 70.69% stake in the company. Shares short for ARWR as of 1741910400 were 10439945 with a Short Ratio of 5.37, compared to 1739491200 on 9431372. Therefore, it implies a Short% of Shares Outstanding of 10439945 and a Short% of Float of 9.83.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
